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Abstract: Benzodiazepines (BZDs) are among the most widely prescribed drugs in developed
countries, but they have a high potential for tolerance, dependence and misuse. High-dose BZD
misuse represents an emerging addiction phenomenon, but data on quality of life (QoL) in high-dose
BZD misusers are scant. This study aimed to explore QoL in high-dose BZD misuse. We recruited
267 high-dose BZD misusers, compared the QoL scores in those who took BZD only to poly-drug
misusers, and explored the role of demographic and clinical covariates through multivariable analysis.
Our data confirmed worse QoL in high-dose BZD misusers and showed that (a) QoL scores were
not negatively influenced by the misuse of alcohol or other drugs, or by coexisting psychiatric
disorders; (b) demographic variables turned out to be the most significant predictors of QoL scores;
(c) BZD intake significantly and negatively influenced QoL. Physical and psychological dimensions
of QoL are significantly lower in high-dose BZD misusers with no significant effect of comorbidities.
Our data suggest that the main reason for poor QoL in these patients is high-dose BZD intake per se.
QoL should be considered among outcome measures in these patients.
Keywords: 12-Items General Health Questionnaire (GHQ-12); addiction; benzodiazepine (BZD); drug
misuse; multivariable analysis; patient-centered outcomes; quality of life (QoL); Short Form-36 (SF-36)
1. Introduction
Benzodiazepines (BZDs) and BZD-related drugs represent a group of gamma-aminobutyric acid
(GABA)-ergic molecules, which are extensively prescribed for a wide range of indications, and they
are one of the most widely used groups of pharmaceuticals worldwide [1]. BZDs are indicated for the
management of anxiety and insomnia, but a short-term prescription is recommended because of their
high potential for tolerance and dependence [2]. Epidemiological figures indicate that 2%–7.5% of the
general population in developed countries [3] and 6%–76% of patients on BZDs become long-term
(i.e., greater than six months) users [2]. The low toxicity coupled with a high potential for tolerance
raises the risk that patients on BZDs increase their daily dosage [4]. It is reported that 20%–50% of
patients on BZDs report some sort of withdrawal when trying discontinuation, and 3%–4% of them
show clear signs of misuse or dependence [1]. Surveys from France, Germany, Italy and the UK suggest
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that 3.2%–3.9% of BZD users exceed the recommended dose [5], and it is estimated that approximately
0.16% of the Swiss adult population are high-dose BZD misusers [6]. High-dose BZD misuse represents
an emerging addiction phenomenon, and it is defined as BZD intake for more than six months, a dose
equivalent >50 mg diazepam/day, and/or an otherwise problematic use of BZDs, such as mixing
BZDs, escalating dosage, using BZDs for recreational purposes, or obtaining BZDs illegally [7,8].
Quality of life (QoL) is a complex concept that is defined as “an individual’s perception of his/her
position in life, in the context of culture and value systems, in which he/she lives and in relation
to his/her goals, expectations, standards, and concerns” [9]. QoL has increasingly been considered
as a prerequisite for the overall health of people, including satisfaction, happiness and well-being.
Converging evidence indicates that addiction or misuse of many drugs, including alcohol, opioids,
and cocaine, may affect QoL [10–15]. Data on QoL of BZD misusers mainly come from poly-drug
misusers [13,16–18] and/or patients with psychiatric comorbidities [19,20], making the understanding
of the specific impact of BZD misuse difficult. A recent study from our group showed lower QoL and
social functioning, along with high levels of psychological distress, in a small group of high-dose BZD
misusers without alcohol or drug co-dependence [8]. However, high-dose BZD misusers frequently
show coexisting psychiatric conditions and/or other drug dependence or misuse, and these factors
may influence QoL together with demographic ones (e.g., age, sex/gender). Whether the interplay of
these factors has an effect on QoL of high-dose BZD misusers has never been explored.
The goal of the present study was to add new pieces of information on QoL in high-dose BZD
misuse. To this aim, we recruited a large group of high-dose BZD misusers, compared the QoL in
patients who misused BZD only (either one or more BZD active principles) to poly-drug misusers
(i.e., BZD plus alcohol or other drugs), and explored the role of demographic and clinical covariates on
QoL scores.
2. Subjects and Methods
2.1. Patients
We recruited 267 patients (age > 18 years), who were consecutively seen from May 2013 to
May 2016 at the Department of Internal Medicine, Addiction Unit, Verona University Hospital, Italy,
for high-dose BZD misuse, which was defined as a diagnosis of BZD dependence according to the
Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM)-IV criteria [21] with
misuse lasting more than six months, and daily BZD intake exceeding at least five times the maximum
daily recommended dose (i.e., >50 mg diazepam/day) [7,8]. In the present study, psychiatric disorders
and addiction to alcohol or other drugs, even if in remission, were not considered as exclusion criteria,
because we were interested in their role as cofactors in influencing QoL.
The dosage of BZDs was standardized as the daily diazepam dose equivalent (DDDE, mg)
according to previous studies [8]. Zolpidem, which is an imidazopyridine compound and is chemically
distinct from BZDs, has been included among BZDs in the present study, since it binds to the alpha-1
subtype of the BZD receptor and its effects are similar to those of BZDs [22].
Demographic (sex; age; education: grade school, high school, university; employment:
unemployed, employed; marital status: single or divorced, engaged or married), and clinical variables
(type of drug misuse: BZD only either one or more active principles, active poly-drug misuse defined
as BZD plus alcohol or other drugs, previous poly-drug misuse; other drugs of misuse: alcohol,
opioids, cocaine, cannabinoids, barbiturates; DDDE: mg; BZD misuse duration: months; presence and
type of coexisting major psychiatric diseases excluding anxiety disorders and mild depression: major
depression, other psychoses, personality disorders) were recorded. Information on these variables was
mainly obtained from medical records. DDDE data were based on self-report. For prior vs. active
poly-drugs misuse, a time frame of 12 months from the time of enrollment was chosen.
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The study was conducted according to the Declaration of Helsinki and approved by the ethics
committee of the Verona University Hospital (study protocol number 875CESC). All patients gave
informed consent for participation to the study.
2.2. Quality of Life Measures
All the patients sat in a quiet room without any disturbing factors and completed two questionnaires,
i.e., the Short Form-36 (SF-36) questionnaire and the 12-item General Health Questionnaire (GHQ-12).
The SF-36 is a generic QoL scale consisting of 36 individual items that are grouped into eight
dimensions: physical functioning (PF), role physical (RF), bodily pain (BP), general health (GH), vitality
(VT), social functioning (SF), role emotional (RE), mental health (MH), with a score from 0 (worst score)
to 100 (best score) for each dimension [23,24].
The GHQ-12 is one of the most widely used screening tool to identify short-term changes in
psychological health and is composed of 12 questions on mood states over the previous two weeks:
lost sleep, feelings of being under strain, could not concentrate, felt unable to play a useful role, could
not face problems, could not make decisions, could not overcome difficulties, felt unhappy, did not
enjoy day-to-day activities, felt depressed, lost confidence, and felt worthless [25]. GHQ-12 answers
were scored on a two-point scale (coded 0-0-1-1), resulting in 0–12 total score range with higher values
indicating more severe psychological distress [26], and a cut-off value of ≥4 [8]. SF-36 and GHQ-12
were administered prior to detoxification with flumazenil infusion [22].
2.3. Statistical Analysis
All tests were carried with the IBM SPSS version 20.0 statistical package. The Fisher’s exact and
the Pearson’s χ2 test were used for categorical variables, while the one-way ANOVA and post-hoc with
Bonferroni’s correction were used for continuous variables in case of normal distribution, otherwise
the non-parametric Mann-Whitney U and Kruskal Wallis tests were applied. Multivariable analysis
was used to explore the influence of the demographic and clinical covariates (sex, age, education,
employment, marital status, type of drug misuse, type of poly-drug misuse, DDDE, BZD misuse
duration, presence and type of coexisting major psychiatric diseases) on QoL measures. Variables
that were unique to poly-drug misusers (e.g., alcohol) were set as 0 in BZD only misusers. Linear
regression model analysis was applied for SF-36 dimensions (continuous dependent variables). Logistic
regression model analysis was used for GHQ-12 (binary dependent variable: ≥4, <4), and the results
were expressed as odd ratios (ORs) and 95% confidence intervals (CI). The goodness of fit of the logistic
regression model was assessed using the Hosmer and Lemeshow test [27]. p < 0.05 (two-tailed) was
taken as the significance threshold for all the tests.
3. Results
3.1. Patients
In our sample, 166 patients misused only BZDs (either one or more BZD active principles),
while 49 were active poly-drug misusers excluding tobacco and 52 were previous poly-drug misusers
in remission at the time of recruitment.
Among demographic variables, only sex and age significantly differed according to the type of
BZD misuse (Table 1). Post-hoc showed a significant age difference for the comparison between BZD
only and active poly-drug misusers.
All 267 patients misused at least one BZD, 39 of them misused two BZDs, and four misused
three different BZDs. The types and frequencies of BZDs (main active principle in case of more
than one BZD) and other drugs of misuse are reported in Table 2. The second most misused BZDs
were alprazolam (n = 10), lormetazepam (n = 4), triazolam (n = 4), lorazepam (n = 3), bromazepam
(n = 2), zolpidem (n = 1), other (n = 15), while the third most misused BZDs were lormetazepam
(n = 1), alprazolam (n = 1), zolpidem (n = 1), other (n = 1). The DDDE ranged from 55 to 2330 mg
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(median = 250 mg). The type of BZD differed according to active poly-drug abuse, but no difference in
DDDE (mg) and BZD misuse duration (months) was found when comparing BZD only vs. poly-drug
misusers (Table 2).
Coexistent major psychiatric diseases (other psychoses and personality disorders) were
significantly more frequent in patients with active poly-drug misuse than those who misused BZDs
only (Table 2).
Table 1. Demographic characteristics of the patients according to the type of high-dose benzodiazepines
(BZD) and poly-drug misuse.
Variable
Type of BZD Misuse
p ValueOnly BZD Misuse
(n = 166)
Previous Poly-Drug Misuse
(n = 52)
Active Poly-Drug Misuse
(n = 49)
Sex (M, F) 33%, 67% 82%, 18% 67%, 33% <0.001 *
Age 45.7 ± 10.7 44.2 ± 8.9 41.4 ± 9.0 0.03 *
Education † 23%, 51%, 26% 33%, 54%, 13% 31%, 53%, 16% n.s.
Employment ‡ 37%, 63% 48%, 52% 45%, 55% n.s.
Marital status § 54%, 46% 69%, 31% 61%, 39% n.s.
M: Male. F: Female. n.s.: Not significant. † Education: grade school, high school, university (%). ‡ Employment:
unemployed, employed (%). § Marital status: single/divorced, engaged/married (%). * Significant statistical
comparison (p < 0.05).
Table 2. Type of BZD misused by patients, daily dosage, misuse duration, other drugs of misuse and
coexisting psychiatric conditions.
Variable
Type of BZD Misuse
p ValueAll Patients
(n = 267)
Active BZD ˆ
(n = 218)
Active Poly-Drug
(n = 49)
Active principle † 0.015 *
Lormetazepam 187 (70.0%) 156 (71.6%) 31 (63.3%)
Alprazolam 22 (8.2%) 17 (7.8%) 5 (10.2%)
Zolpidem 22 (8.2%) 20 (9.2%) 2 (4.1%)
Lorazepam 12 (4.5%) 6 (2.8%) 6 (12.2%)
Bromazepam 10 (3.7%) 7 (3.2%) 3 (6.1%)
Triazolam 4 (1.5%) 2 (0.9%) 2 (4.1%)
Other BZDs 10 (3.7%) 10 (4.5%) 0 (0.0%)
DDDE (mg) ‡ 394.5 ± 392.0 406.2 ± 401.1 365.9 ± 324.5 n.s.
Misuse duration (mos) 74.9 ± 69.8 75.7 ± 72.1 71.4 ± 58.3 n.s.
Other drugs of misuse § n.a.
Alcohol 39/33/29 25/27/0 14/6/29
Opioids 70/26/5 37/15/0 33/11/5
Cocaine 47/43/11 29/23/0 18/20/11
Cannabinoids 57/35/9 32/20/0 25/15/9
Barbiturates 96/3/1 50/1/0 46/2/1
Psychiatric diseases ¶ 164 (61.4%) 125 (57.3%) 39 (79.6%) 0.004 *
Major depression 145 (54.3%) 125 (45.9%) 20 (40.8%) n.s.
Other psychoses 28 (10.5%) 15 (11.7%) 13 (26.5%) <0.001 *
Personality disorders 22 (8.2%) 13 (6.0%) 9 (18.4%) 0.009 *
DDDE: Daily diazepam dose equivalent. mos: Months. n.s.: Not significant. n.a.: Not applicable. † Main BZD in
case of misuse of different BZDs. ‡ Sum of all the DDDEs in case of poly BZD misuse. § Other drugs of misuse:
No/previous/active. ¶ Psychiatric diseases: Coexisting major conditions excluding anxiety disorders and mild
depression. ˆ Active BZD: BZD only misuse + Previous poly-drug misuse. * Significant statistical comparison
(p < 0.05).
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3.2. Quality of Life Measures
None of the SF-36 dimensions was significantly different when comparing patients who misused
BZD only vs. poly-drug misusers, either previous or active (Mann-Whitney U test: n.s. for all
dimensions; Figure 1).
The comparison was repeated by exploring active BZD misuse (i.e., BZD only misuse + previous
poly-drug misuse; n = 218) vs. active poly-drug misuse (n = 49), but again none of the SF-36 dimensions
turned out to be significantly different between the two groups (Mann-Whitney U test).
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By using the cut-off value of ≥4 for the GHQ-12 score, 122 out of the 166 patients who misused
BZD only (73.5%) and 79 of the 101 either previous or active poly-drug misusers (78.2%) showed
severe psychological distress (Fisher’s exact test: n.s.).
The severe psychological distress was slightly higher in the 218 active BZD misusers (81.6%) than
in the 49 active poly-drug misusers (70.2%), but the difference did not reach statistical significance
(Fisher’s exact test: n.s.).
The multivariable linear regression model was applied to explore the influence of demographic
and clinical covariates on SF-36 scores. Among demographic variables, age significantly influenced
all SF-36 dimension scores (i.e., higher scores in older patients but to a variable extent according to
the SF-36 dimension), while sex (i.e., higher BP, VT and MH scores in males), education (i.e., higher
PF, BP, GH, VT and MH scores in patients with higher education), employment (i.e., higher PF and
GH scores in employed patients), and marital status (i.e., higher PF, VT and MH scores in engaged or
married patients) were found to significantly influence some SF-36 scores, but these findings were not
consistent across all SF-36 dimensions (Table 3).
Among clinical variables, only poly-drug misuse, either active or previous, was found to
significantly influence PF (i.e., higher PF score in patients with poly-drug misuse than in those
on BZDs only), and DDDE significantly influenced SF (i.e., higher SF score in patients who took
less DDDE), but the other clinical variables, including active poly-drug misuse, did not significantly
influence SF-36 scores (Table 3).
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The multivariable logistic regression model showed that each unitary increment of DDDE (mg)
significantly influenced the risk of a GHQ-12 score ≥4 (OR = 1.01, 95% CI: 1.00–1.02, p = 0.012), while
the remaining covariates were not significant.
Table 3. Linear regression model analysis for the SF-36 dimensions.
SF-36 Dimensions and Significant Covariates β 95% CI p Value
Physical functioning (PF)
Age (year) 1.19 1.01; 1.37 <0.001
Education 8.96 3.81; 14.12 0.001
Employment 10.94 3.70; 18.18 0.003
Marital status 8.53 0.84; 16.22 0.030
Poly-drug misuse (either active or previous) 14.69 7.58; 21.80 <0.001
Role physical (RF)
Age (year) 0.68 0.58; 0.79 <0.001
Bodily pain (BP)
Sex −9.66 −17.70; −1.60 0.019
Age (year) 1.10 0.92; 1.28 <0.001
Education 9.98 4.18; 15.79 0.001
General health (GH)
Age (year) 0.90 0.75; 1.04 <0.001
Education 5.61 1.37; 9.84 0.010
Employment 7.06 1.18; 12.94 0.019
Vitality (VT)
Sex −9.55 −14.70; −4.40 <0.001
Age (year) 0.87 0.75; 0.99 <0.001
Education 4.32 0.78; 7.87 0.017
Marital status 6.99 1.48; 12.50 0.013
Social functioning (SF)
Age (year) 0.83 0.65; 1.01 <0.001
DDDE (mg) −0.02 −0.01; −0.04 0.026
Role emotional (RE)
Age (year) 0.71 0.56; 0.87 <0.001
Mental health (MH)
Sex −7.39 −12.95; −1.83 0.009
Age (year) 0.95 0.82; 1.08 <0.001
Education 4.92 1.09; 8.75 0.012
Marital status 7.38 1.43; 13.32 0.015
Here are reported only covariates that turned out to be significant in multivariable linear regression analysis.
Please note that higher SF-36 scores indicated higher quality of life levels. Sex: 0 = male, 1 = female; education:
0 = grade school, 1 = high school, 2 = university; employment: 0 = unemployed, 1 = employed; marital status:
0 = single or divorced, 1 = engaged or married; poly-drug misuse: 0 = no, 1 = yes. DDDE: Daily diazepam dose
equivalent. SF-36: Short Form-36.
4. Discussion
Our data confirmed worse QoL in high-dose BZD misusers in comparison to that expected
in the reference Italian population [8,24], and offered these new findings, which will be discussed
below: (a) SF-36 scores and the percentage of patients with a GHQ-12 score ≥4 were not significantly
influenced by the misuse of alcohol or other drugs; (b) poly-drug misuse resulted in a higher PF
score in comparison to misuse of BZD only; (c) coexisting psychiatric disorders did not influence QoL
outcomes; (d) demographic variables turned out to be the most significant predictors of SF-36 scores;
(e) BZD intake expressed as DDDE significantly and negatively influenced SF and the risk of a GHQ-12
score ≥4.
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Patients’ self-reported outcomes have become an increasingly important source of information in
health care [11]. QoL measures may provide insight into a broader perspective on physical, mental and
social health [11,28], and may help to gradually shift the clinical focus from a cure to the enhancement
of this outcome [29]. This view fits well with the recognition that substance misuse is a chronic,
relapsing disorder that may have negative consequences on various life domains [29–32]. Early QoL
studies among patients with substance use disorders did not allow general conclusions due to the
small number of studies, the small samples, and the use of different measures (i.e., health-related QoL,
general QoL) and tools [31], but more recent reports offered more insight on this topic [29].
All SF-36 dimensions were worse than those in the general population in the present study.
This finding confirmed that from a previous report from our group in a small group of high-dose BZD
patients seeking detoxification, without either poly-drug misuse or mental disorders [8]. The present
results offer a broader view on this topic, because the sample size was larger, and we included patients
with coexisting psychiatric conditions and/or other drug dependence or misuse, offering a more
real-life scenario and allowing the exploration of the influence of each single variable on QoL scores
through multivariable analysis.
Data from other substance use disorders indicate an overall reduction of QoL [29]. Despite studies
investigating QoL in opiate-dependent individuals used different tools, a systematic review and recent
data indicate that these patients show lower QoL scores compared with the general population and
people with various medical illnesses [9,11], and that methadone treatment can ameliorate QoL [33].
General and disease-specific QoL measures are lower in patients with alcohol misuse and dependence,
but may be improved by treatment and successful abstinence [29,34]. Some reports did not detect
any impact of cocaine use on QoL [29], while other ones demonstrated QoL impairment in the initial
phase of drug dependence, and a correlation between the severity of cocaine dependence and QoL [10].
Data on nicotine misuse are more contradictory. While ex-smokers appear to have higher QoL scores
in comparison to current smokers [29,35], patients attempting to quit smoking show a decrease in
QoL [36]. It is conceivable that the reason for worse QoL in patients with substance use disorders may
include the disruption of normal daily life activities and social contacts in relation to the time and
money required to obtain the drug of misuse, and the physical, emotional and cognitive side effects of
the drug [8].
Quite surprisingly, the presence of poly-drug misuse did not lower QoL scores in our sample.
Interestingly, any poly-drug misuse, i.e., either active or previous, resulted in a higher SF-36 PF than
the misuse of BZD only. Furthermore, active poly-drug misuse was not found to influence (i.e., either
significantly reduce or increase) any of the QoL scores in multivariable analysis. Our findings seem
to be in contrast with the previous literature, which showed that the concurrent dependence or
misuse of two substances is associated with worse QoL [37]. We may speculate that, in our patients,
high-dose BZD misuse resulted in such a severe reduction of QoL measures that the concurrent
substance use disorder could not cause a lower score of this outcome because of a ceiling effect.
Our hypothesis is in keeping with recent data showing that QoL in high-dose BZD misuse was worse
than in heroin-addicted patients, despite the latter ones being treated by methadone [38].
Previous studies documented a negative effect of mental disorders on QoL [39,40]. Psychiatric
comorbidity was not found to significantly influence QoL measures in our patients. This is in keeping
with data from opiate dependence, where no difference was found between QoL scores in patients with
and those without psychiatric disorders [41]. In contrast, a recent report showed that patients with
substance use disorders (alcohol, cannabis, cocaine) and psychiatric comorbidity evaluated their QoL
more negatively than those without psychiatric comorbidity [42]. It is difficult, however, to disentangle
the directionality of the association between mental health issues and drug misuse and dependence
in substance use disorders, because patients with psychiatric diseases may misuse substances they
have been prescribed, and mental health problems may be secondary to drug misuse [34]. In our
study, anxiety and mild depression were not considered as psychiatric comorbidities because these two
conditions are very common in high-dose BZD misuse, but they may play a role in worsening QoL.
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In accordance with previous studies on QoL in patients with substance use disorders, demographic
variables that resulted in worse QoL scores in our patients were female sex, unemployment, and being
single or divorced [8,9,34]. While the negative effect of being unemployed and single/divorced can
be easily understood, the reason for worse QoL in women may stem from the significantly higher
prevalence of anxiety and depression in comparison to men [43].
We found a significant positive effect of age on most SF-36 dimensions in our cohort of patients.
This finding is difficult to compare with previous studies, because of the lack of data on the effect of
age on QoL in other substance use disorders. Age was found to significantly influence QoL, either
positively or negatively, in normal controls, with a prevalent negative effect because of aging-related
problems [44]. We may speculate that the young-to-middle age of our sample could have mitigated
the potentially negative influence of physical problems secondary to aging and their limitations on
daily activities and physical functioning [44]. Future studies should confirm this hypothesis.
We documented that BZD intake, expressed as DDDE, significantly reduced the SF score and
enhanced the risk of a GHQ-12 score≥4. Data from low-dose BZD users showed that initial BZD intake
caused improvement in QoL, likely because of anxiety reduction without consistent side effects [45].
Taken together, these data suggest that limited duration of use and low BZD dosage, as suggested
by guidelines [1], may improve QoL, while chronic misuse and very high doses, as in our sample,
consistently reduce physical and emotional QoL dimensions.
A limitation of the present study is that DDDE was based on patients’ self-reporting and the
presence of alcohol and other drug co-misuse was not confirmed by urine toxicology. Another
limitation is the cross-sectional design and the absence of a follow-up to evaluate QoL changes in
response to treatment. Other limitations include the sample of convenience from a single treatment
hospital, the limited availability of covariates representing clinical characteristics, the absence of
correction for multiple comparisons, and the generalizability of results to low-dose BZD users or
those not in treatment for high-dose BZD misuse. Evidence from low-dose BZD [18] and other drugs
of misuse (e.g., opioids, alcohol) [11,33,34] indicates that treatment results in improved QoL. Future
studies should follow up with patients after successful treatment for BZD misuse to better explore the
specific contribution to QoL of high-dose BZDs, and whether QoL might represent a relevant outcome
measure in this field or a prognostic factor for detoxification-seeking or drug misuse relapse [46].
5. Conclusions
In conclusion, we confirmed that physical and psychological dimensions of QoL were significantly
lower in high-dose BZD misusers, and that comorbidities (i.e., poly-drug misuse, psychiatric diseases)
did not influence QoL scores. These data suggest that the main reason for poor QoL in these patients is
high-dose BZD intake per se. Since the administration of a QoL instrument takes roughly 10–15 min,
expanding our knowledge on areas of deficit would enable more focused interventions aimed to
address specific QoL dimensions [34].
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